Enabling Novel Pharmaceutical Therapies through 3D-Printing

Aprecia continues its leadership position in the pharmaceutical application of 3D-Printing. Aprecia will be launching its two new platforms later this year that will provide additional benefits in early development FIH clinical as well as small and large scale commercial production. In this presentation, Aprecia will discuss the flexibility and precision these platform provide in delivering novel products to the market.

A presentation by Kirk Donaldson, Vice President of Business Development and Alliance Management at Aprecia Pharmaceuticals.

The view of the speaker

Question 1: What drives you?
I’m driven by the opportunity to help bring better products to the market. I experienced Aprecia’s ZipDose tablet in 2011, and knew then that I wanted to help bring the benefits of ZipDose to the patients who deserve better therapy options. In 2019, after spending 8 years in the CDMO, CMO, and CRO world I was given the opportunity the realize this opportunity and help Aprecia deliver its vision to be the global leader in new technologies that address unmet healthcare needs

Question 2: Why should the delegate attend your session?
Aprecia continues to advance the capabilities of its 3D-Printing platforms and the flexibility of applying its ZipDose rapidly disintegrating technology to a wide range of functionally designed particles. This presentation will provide an update on the wide range of capabilities Aprecia can provide in formulation development and dosage form design.

Question 3: What emerging technologies / trends do you see as having the greatest potential in the short and long run?
I believe the ability to deliver small and large volumes in centralized facilities through 3D-Printing will have a major impact in the short term to develop better products in areas like rare/orphan disease or pediatrics by leveraging current regulatory pathways to accelerate development and commercialization of new products. The application of this technology moved closer to the patient in a regional or local distribution/mfg center will provide long term benefit for mass personalization of medicine where quality, cost, speed, and safety can be ensured.

Question 4: What kind of impact do you expect them to have?
see above

Question 5: What are the barriers that might stand in the way?
The only barriers I believe keeping the industry from making this shift is the pharma industry realizing the benefits 3D-Printing can provide to patients, caregivers, and the pharmaceutical companies and making the decision to shift from the convectional technologies that currently fill their large facilities. Aprecia approaches this with partnership in mind, allowing its partners to leverage its leadership position in the marketplace to develop and deliver novel dosage forms in its state of the art facility in Blue Ash, OH.

About Kirk Donaldson
Kirk joined Aprecia from MEDPACE where he served as the Associate Director of Account Management. Prior to MEDPACE, he held various management position at Patheon (Thermo Fisher Scientific), including Senior Global Business/Alliance Manager. Donaldson started his pharmaceutical career with Prasco, where he served as the Manager of Business Analytics.

About Aprecia Pharmaceuticals
Aprecia is the global leader in commercial-scale 3DP for pharmaceutical manufacturing technology. We’re committed to creating new solutions for unmet healthcare needs by developing pharma-ready innovations and complementary technology platforms that enable patient-centric products and help take medicine to its fullest potential.

Kirk Donaldson is speaker at the 2022 edition of the 3D Pharma Printing Conference which is a part of the 3D Medical Printing Series

Leave a Reply

Your email address will not be published.